Population-based serosurveys for SARS-CoV-2 transmission 2021–2022, Massachusetts USA

This survey indicates that while there was an increase in antibodies to spike protein and to associated neutralizing antibodies over time, there were no differences in neutralizing antibodies by socio-demographic factors, suggesting no major health disparities existed at the time of surveys in either vaccine coverage or infection-related antibody titers across the state. Response rates were higher among some demographic groups (Caucasians, households with a high income, and women), thus, oversampling and weighting allowed estimates of the larger Massachusetts population. Our findings that there were no statistically significant differences in neutralizing antibodies across demographic groups suggesting all groups were similarly protected from SARS-CoV-2 infection. These results highlight the success of Massachusetts in protecting individuals across all demographics.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2025-11-20
DOI
https://doi.org/10.1016/j.vaccine.2025.127952
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Population-based serosurveys for SARS-CoV-2 transmission 2021–2022, Massachusetts USA

John Cluverius, R. Monina Klevens, Estee Y. Cramer, Joshua J. Dyck et al.
Vaccine
SARS-CoV-2 and COVID-19 Research
article

Population-based serosurveys for SARS-CoV-2 transmission 2021–2022, Massachusetts USA

John Cluverius, R. Monina Klevens, Estee Y. Cramer, Joshua J. Dyck, Mark Melnik, Andrew A. Lover, Jessica Pearlman, Augustine Olajide Dada, Peter H. Reinhart, Shauna Onofrey, Megan E. Hatch, Laura Harris, Ashley Eaton, Rebecca Loveland
article en

Abstract

This survey indicates that while there was an increase in antibodies to spike protein and to associated neutralizing antibodies over time, there were no differences in neutralizing antibodies by socio-demographic factors, suggesting no major health disparities existed at the time of surveys in either vaccine coverage or infection-related antibody titers across the state. Response rates were higher among some demographic groups (Caucasians, households with a high income, and women), thus, oversampling and weighting allowed estimates of the larger Massachusetts population. Our findings that there were no statistically significant differences in neutralizing antibodies across demographic groups suggesting all groups were similarly protected from SARS-CoV-2 infection. These results highlight the success of Massachusetts in protecting individuals across all demographics.

VaccineVol. 69
University of Massachusetts Lowell (US), Massachusetts Department of Public Health (US), University of Massachusetts Amherst (US)
Openalex Percentile: Top 59%
SARS-CoV-2 and COVID-19 Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Population-based serosurveys for SARS-CoV-2 transmission 2021–2022, Massachusetts USA — John Cluverius, R. Monina Klevens, et al. · Vaccine (2025) | TGRS Research Map | TGRS